Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
View Patent ↗The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.
1. A method for delivering a bioactive agent to an internal tissue of a subject comprising the steps of:
providing an insertable medical device comprising:
an expandable elastic portion having a coating comprising a flexible biostable hydrogel matrix selected from the group consisting of poly(acrylamide), poly(methacrylamide), poly(vinylpyrrolidone), poly(acrylic acid), poly(ethylene glycol), poly(vinyl alcohol), poly(HEMA), methyl vinyl ether/maleic anhydride copolymers, and vinyl pyrrolidone/(meth)acrylamide copolymers on the expandable elastic portion and a polymer having pendent reacted photogroups that covalently bonds to the flexible biostable hydrogel matrix, and
microparticulates associated with the flexible biostable hydrogel matrix, the microparticulates comprising a bioactive agent and having an average greatest dimension in a range of 0.1 μm to 50 μm;
inserting the medical device into a subject, and
expanding the expandable elastic portion in the subject, wherein a portion greater than 20% of the microparticulates become disassociated upon the expansion to contact the flexible biostable hydrogel matrix with the internal tissue of the subject and are released into the subject, and wherein bioactive agent is released from the microparticulates to provide a therapeutic effect to the internal tissue of the subject.
2. The method of claim 1 wherein the microparticulates have an average greatest dimension in a range of 1-3 μm.
3. The method of claim 1 , wherein the expandable elastic portion is all or a portion of a balloon, the balloon capable of being folded in a compacted configuration for inserting the medical device into the subject.
4. The method of claim 1 , wherein the microparticulates include a control release agent, the control release agent capable of eroding, dissolving, or degrading in a presence of body fluid.
5. The method of claim 1 wherein a majority of the associated microparticulates are non-homogenously distributed in the flexible biostable hydrogel matrix and are associated on an outer surface of the flexible biostable hydrogel matrix.
6. The method of claim 1 wherein the pendent reacted photogroups comprise a reacted aryl ketone photogroup.
7. The method of claim 1 , wherein the flexible biostable hydrogel matrix has a thickness in a range of 5-100 μm.
8. The method of claim 1 wherein the microparticulates are formed entirely or almost entirely of a bioactive agent in neat form.
9. A method for delivering a bioactive agent to an internal tissue of a subject comprising the steps of:
providing an insertable medical device comprising:
an expandable elastic balloon portion having a coating comprising a flexible biostable hydrogel matrix selected from the group consisting of poly(acrylamide), poly(methacrylamide), poly(vinylpyrrolidone), poly(acrylic acid), poly(ethylene glycol), poly(vinyl alcohol), poly(HEMA), methyl vinyl ether/maleic anhydride copolymers, and vinyl pyrrolidone/(meth)acrylamide copolymers on the expandable elastic balloon portion, the matrix further comprising a polymer having pendent reacted aryl ketone photogroups that covalently bond the polymer to a target selected from other polymers in the flexible biostable hydrogel matrix and a coated surface of the expandable elastic portion, and
microparticulates associated with the flexible biostable hydrogel matrix, the microparticulates comprising a bioactive agent and having an average greatest dimension in a range of 0.1 μm to 50 μm;
inserting the medical device into a subject wherein the expandable elastic balloon portion is folded in a compacted configuration, and
expanding the expandable elastic balloon portion in the subject, wherein a portion greater than 20% of the microparticulates become disassociated upon the expansion to contact the flexible biostable hydrogel matrix with the internal tissue of the subject and are released into the subject, and wherein bioactive agent is released from the microparticulates to provide a therapeutic effect to the internal tissue of the subject.
10. The method of claim 9 wherein the microparticulates have an average greatest dimension in the range of 1-3 μm.
11. The method of claim 9 , wherein the microparticulates include a control release agent, the control release agent capable of eroding, dissolving, or degrading in a presence of body fluid.
12. The method of claim 1 , wherein the flexible biostable hydrogel matrix has a thickness in the range of 5-100 μm.